Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial
年龄和性别对雷莫芦单抗联合紫杉醇作为一线奥沙利铂化疗的转换维持治疗与继续治疗的疗效和安全性的影响：ARMANI III期试验的亚组分析
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105329
Fazio, R; Randon, G; Bergamo, F; Palermo, F; Tamberi, S; Giommoni, E; Di Donato, S; Fornaro, L; Brunetti, O; De Vita, F; Valgiusti, M; Gobba, S M; Spallanzani, A; Murgioni, S; Bethaz, V; Strippoli, A; Latiano, T P; Cardellino, G G; Ceccon, C; Raimondi, A; Prisciandaro, M; Pircher, C C; Ambrosini, M; Manca, P; Fassan, M; Di Bartolomeo, M; Di Maio, M; Pietrantonio, F
